These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7527236)

  • 1. Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis.
    Saifuddin M; Ghassemi M; Patki C; Parker CJ; Spear GT
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):829-37. PubMed ID: 7527236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.
    Saifuddin M; Parker CJ; Peeples ME; Gorny MK; Zolla-Pazner S; Ghassemi M; Rooney IA; Atkinson JP; Spear GT
    J Exp Med; 1995 Aug; 182(2):501-9. PubMed ID: 7543140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
    Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.
    Schmitz J; Zimmer JP; Kluxen B; Aries S; Bögel M; Gigli I; Schmitz H
    J Clin Invest; 1995 Sep; 96(3):1520-6. PubMed ID: 7544808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
    Kuraya M; Yefenof E; Klein G; Klein E
    Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement.
    Marschang P; Sodroski J; Würzner R; Dierich MP
    Eur J Immunol; 1995 Jan; 25(1):285-90. PubMed ID: 7531147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diminished expression of cell-surface complement regulatory proteins in HIV-infected children and with HIV infection of peripheral blood mononuclear cells in vitro.
    Jarvis JN; Taylor H; Long PM; Gutta PV; Pousak T; Fine N
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):249-56. PubMed ID: 7540489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
    Saifuddin M; Hedayati T; Atkinson JP; Holguin MH; Parker CJ; Spear GT
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1907-11. PubMed ID: 9266986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.
    Sohn JH; Kaplan HJ; Suk HJ; Bora PS; Bora NS
    Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3492-502. PubMed ID: 11006244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.
    Varsano S; Frolkis I; Rashkovsky L; Ophir D; Fishelson Z
    Am J Respir Cell Mol Biol; 1996 Dec; 15(6):731-7. PubMed ID: 8969267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.
    Charreau B; Cassard A; Tesson L; Le Mauff B; Navenot JM; Blanchard D; Lublin D; Soulillou JP; Anegon I
    Transplantation; 1994 Dec; 58(11):1222-9. PubMed ID: 7527603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV-1 particles as a function of complement-mediated virolysis.
    Nakamura M; Okada H; Sasaki H; Yoshida K; Kamada M; Okada N; Terada M; Ohno T
    Microbiol Immunol; 1996; 40(8):561-7. PubMed ID: 8887350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
    Mäenpää A; Junnikkala S; Hakulinen J; Timonen T; Meri S
    Am J Pathol; 1996 Apr; 148(4):1139-52. PubMed ID: 8644856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
    Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
    Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55).
    Holmes CH; Simpson KL; Okada H; Okada N; Wainwright SD; Purcell DF; Houlihan JM
    Eur J Immunol; 1992 Jun; 22(6):1579-85. PubMed ID: 1376264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.
    Hu W; Yu Q; Hu N; Byrd D; Amet T; Shikuma C; Shiramizu B; Halperin JA; Qin X
    J Immunol; 2010 Jan; 184(1):359-68. PubMed ID: 19955519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
    Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
    Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.